Incyte Corporation

07/14/2021 | Press release | Distributed by Public on 07/14/2021 15:04

Incyte Announces Positive Phase 3 REACH3 Study Data Published in NEJM for Ruxolitinib (Jakafi®) in Chronic Graft-Versus-Host Disease